<DOC>
	<DOCNO>NCT01336634</DOCNO>
	<brief_summary>Dabrafenib potent selective inhibitor BRAF kinase activity . This Phase II , non-randomized , open-label study ass efficacy , safety , tolerability dabrafenib administer single agent combination trametinib stage IV disease subject BRAF mutant advance non-small cell lung cancer . Subjects receive dabrafenib 150 mg twice daily ( BID ) monotherapy treatment dabrafenib 150 mg bid trametinib 2 mg daily combination therapy continue treatment disease progression , death , unacceptable adverse event .</brief_summary>
	<brief_title>Study Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily Combination With Dabrafenib Twice Daily Trametinib Once Daily Combination Therapy Subjects With BRAF V600E Mutation Positive Metastatic ( Stage IV ) Non-small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Signed write informed consent ; Histologically cytologically confirm nonsmall cell cancer lung ( NSCLC ) stage IV ( accordingto AJCC Staging 7th Edition ) ; For Cohorts A B , document tumor progression ( base radiological imaging ) receive least one prior approve platinumbased chemotherapy regimen advance stage/metastatic NSCLC . An alternate chemotherapeutic agent/regimen acceptable substitute event subject intolerant , ineligible receive platinum base chemotherapy . Subjects enrol Cohort B 3 prior systemic treatment advance stage/metastatic NSCLC ( neoadjuvant adjuvant therapy count number prior regimens maintenance therapy count separate regimen ) . Subjects Cohort C require receive prior systemic anticancer therapy metastatic disease ( i.e. , dabrafenib/trametinib 1st line treatment metastatic disease ) ; Measurable disease accord Response Evaluation Criteria Solid Tumors [ RECIST 1.1 ] ; At least 18 year age ; Anticipated life expectancy least three month ; Presence BRAF V600E mutation lung cancer tissue . Mutation must locally confirm CLIAcertified laboratory ( equivalent ) . An adequate amount tumor tissue ( archived tumor tissue , fresh biopsy archive tissue available ) must available time enrolment central validation BRAF mutation ; Able swallow retain oral medication ; Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception study ; NOTE : Oral contraceptive reliable due potential drugdrug interaction dabrafenib . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 ; Must adequate organ function define follow baseline value : Absolute neutrophil count ( ANC ) &gt; /=1.5x10^9/L Hemoglobin &gt; /=9 g/dL Platelets &gt; /=100x10^9/L Prothrombin time /International normalize ratio ( INR ) partial thromboplastin time &lt; /=1.5xULN ( Subjects receive anticoagulation treatment may allow participate INR establish within therapeutic range prior start study treatment . ) Total bilirubin &lt; /=1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5xULN Serum creatinine &lt; /=1.5 mg/dL ( serum creatinine &gt; 1.5 mg/dL , calculate creatinine clearance use standard Cockcroft Gault ; creatinine clearance must &gt; 50 mL/min ) ; creatinine clearance &gt; /= 50 mL/min Left ventricular ejection fraction &gt; /= institutional low limit normal ECHO French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category Previously test presence EGFR ALK mutation lung cancer tissue confirm CLIAcertified laboratory ( equivalent ) . Subjects EGFR ALK mutation eligible previously receive EGFR ALK inhibitor ( ) respectively . Previous treatment BRAF inhibitor ( include limit dabrafenib , vemurafenib , LGX818 , XL281/BMS908662 ) MEK inhibitor ( include limit trametinib , AZD6244 , RDEA119 ) prior start study treatment ( Note : Prior treatment dabrafenib allow crossover subject Cohort A ) ; AntiCancer therapy include chemotherapy , radiationtherapy , immunotherapy , biologic therapy major surgery within 14 day prior start study treatment ( Note : Dabrafenib monotherapy within 14 day prior start combination therapy allow crossover subject Cohort A ) ; Use investigational anticancer drug within 14 day 5halflives ( minimum 14 day ) , prior start study medication ( Note : Dabrafenib monotherapy within 14 day prior start combination therapy allow crossover subject Cohort A ) ; Current use prohibit medication expect require medication treatment study treatment . Unresolved toxicity National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI CTCAE v4.0 ) Grade 2 high previous anticancer therapy , except alopecia ; Presence active gastrointestinal disease condition interfere significantly absorption drug . If clarification need whether condition significantly affect absorption drug , contact GSK medical monitor guidance enrol subject ; Known Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection . Subjects laboratory evidence clear HBV HCV infection may enrol ; History another malignancy &lt; 3 year prior start study treatment malignancy confirm activating RASmutation ; Exceptions : Subjects follow malignancy within 3 year ( include malignancy confirm activate RASmutation ) eligible : ( ) history completely resect skin cancer , ( b ) successfully treat situ carcinoma , ( c ) chronic lymphocytic lymphoma ( CLL ) stable remission , ( ) indolent prostate cancer ( definition : clinical stage T1 T2a , Gleason score &lt; = 6 , prostate specific antigen [ PSA ] &lt; 10 ng/mL ) require antihormonal therapy histologically confirm tumour lesion clearly differentiate lung cancer target nontarget lesion eligible Subjects brain metastasis exclude brain metastasis : Symptomatic OR Treated ( surgery , radiation therapy ) clinically radiographically stable 3 week local therapy ( assess contrast enhance magnetic resonance image [ MRI ] compute tomography [ CT ] ) , OR Asymptomatic untreated &gt; 1 cm long dimension A history evidence cardiovascular risk include follow : Corrected QT ( QTc ) interval &gt; =480 msec History acute coronary syndrome ( include myocardial infarction unstable angina ) within 6 month prior first dose study treatment Coronary angioplasty , stenting within past 24 week ; A history evidence current Class II , III , IV heart failure define New York Heart Association ( NYHA ) guideline ; Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmHg control antihypertensive therapy ; Abnormal cardiac valve morphology ( &gt; =Grade 2 ) document echocardiogram ( subject Grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study ; Patients intracardiac defibrillator A history evidence current clinically significant uncontrolled arrhythmia ; Exception : Subjects atrial fibrillation control &gt; 30 day prior randomization eligible . Uncontrolled medical condition ( i.e. , diabetes mellitus , hypertension , etc . ) , psychological , familial , sociological , geographical condition interfere subject 's safety obtaining informed consent permit compliance protocol ; unwillingness inability follow procedure require protocol ; Pregnant , actively breastfeed female . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) Additional Exclusion Criteria dabrafenib trametinib combination therapy ( Cohort B C well subject crossover monotherapy combination therapy ) : History interstitial lung disease pneumonitis A history current evidence retinal vein occlusion ( RVO ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BRAF V600E</keyword>
	<keyword>trametinib</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>Oncology</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>